These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34745146)

  • 1. MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response.
    Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Luciano A; Barbieri A; Palma G; Scognamiglio G; Di Mauro A; Di Bonito M; Tornesello ML; Buonaguro FM; Vitagliano L; Caporale A; Ruvo M; Buonaguro L
    Front Immunol; 2021; 12():769799. PubMed ID: 34745146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
    Wei P; Jordan KR; Buhrman JD; Lei J; Deng H; Marrack P; Dai S; Kappler JW; Slansky JE; Yin L
    Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34074778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
    Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
    Front Immunol; 2019; 10():3016. PubMed ID: 31969886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy.
    Cavalluzzo B; Ragone C; Mauriello A; Petrizzo A; Manolio C; Caporale A; Vitagliano L; Ruvo M; Buonaguro L; Tagliamonte M
    J Transl Med; 2021 Feb; 19(1):89. PubMed ID: 33637105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orchestrated Codelivery of Peptide Antigen and Adjuvant to Antigen-Presenting Cells by Using an Engineered Chimeric Peptide Enhances Antitumor T-Cell Immunity.
    Pan H; Yu S; Zhuang H; Yang H; Jiang J; Yang H; Ren S; Luo G; Yu X; Chen S; Lin Y; Sheng R; Zhang S; Yuan Q; Huang C; Zhang T; Li T; Ge S; Zhang J; Xia N
    Cancer Immunol Res; 2024 Jul; 12(7):905-920. PubMed ID: 38631019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.
    Jordan KR; McMahan RH; Kemmler CB; Kappler JW; Slansky JE
    Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4652-7. PubMed ID: 20133772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
    J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.
    Qiu F; Becker KW; Knight FC; Baljon JJ; Sevimli S; Shae D; Gilchuk P; Joyce S; Wilson JT
    Biomaterials; 2018 Nov; 182():82-91. PubMed ID: 30107272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
    van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
    Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
    Harao M; Mittendorf EA; Radvanyi LG
    BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
    Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
    J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm.
    Woelke AL; von Eichborn J; Murgueitio MS; Worth CL; Castiglione F; Preissner R
    PLoS One; 2011; 6(8):e23257. PubMed ID: 21858048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heteroclitic immunization induces tumor immunity.
    Dyall R; Bowne WB; Weber LW; LeMaoult J; Szabo P; Moroi Y; Piskun G; Lewis JJ; Houghton AN; Nikolić-Zugić J
    J Exp Med; 1998 Nov; 188(9):1553-61. PubMed ID: 9802967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.